Suppr超能文献

关于2型糖尿病心脏相关挑战整体护理中患者与医生观点的播客

A Podcast on Patient and Physician Perspectives in the Holistic Care of Heart-Related Challenges of Type 2 Diabetes.

作者信息

Rich Jonathan D, Ferguson-Davis Hyvelle

机构信息

Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Patient Author, Heart Sistas, North Lauderdale, FL, USA.

出版信息

Diabetes Ther. 2025 Feb;16(2):137-144. doi: 10.1007/s13300-024-01669-5. Epub 2024 Dec 28.

Abstract

Type 2 diabetes (T2D) frequently coexists with cardiorenal complications. Therefore, a holistic approach to patient management is required, with specialists such as primary care physicians, cardiologists, endocrinologists, and nephrologists working together to provide patient care. Although glycemic control is important in the management of T2D, patients with T2D and acceptable glycemic control are still at risk from cardiovascular (CV) events such as stroke, heart attack, and heart failure (HF). Therefore, management of other risk factors, such as high blood pressure, high cholesterol, smoking cessation, and excess bodyweight, are imperative for reducing the risk of CV disease and HF in patients with T2D. In addition to pharmacological interventions, patient self-care, including beneficial dietary changes, regular exercise, and smoking cessation are critical for improving heart health and reducing the risk of CV events and progression of HF. In this podcast, a patient with lived experience of the heart-related challenges of T2D and a cardiologist discuss the link between T2D and heart-related complications, the pharmacological interventions and lifestyle modifications that can be used to reduce the risk of CV events and prevent HF, and the complexities of engaging with the healthcare system when managing multiple comorbidities. The discussion highlights the importance of patient education and empowerment for the management of heart-related challenges of T2D, and the central role of collaborative care between physicians of multiple specialties to reduce CV risk for patients with T2D.

摘要

2型糖尿病(T2D)常与心肾并发症并存。因此,需要采用整体方法来管理患者,由初级保健医生、心脏病专家、内分泌专家和肾病专家等专科医生共同协作提供患者护理。虽然血糖控制在T2D管理中很重要,但血糖控制尚可的T2D患者仍有发生中风、心脏病发作和心力衰竭(HF)等心血管(CV)事件的风险。因此,管理其他风险因素,如高血压、高胆固醇、戒烟和超重,对于降低T2D患者的心血管疾病和HF风险至关重要。除了药物干预外,患者自我护理,包括有益的饮食改变、定期锻炼和戒烟,对于改善心脏健康、降低CV事件风险和HF进展至关重要。在本播客中,一位有T2D心脏相关挑战亲身经历的患者和一位心脏病专家讨论了T2D与心脏相关并发症之间的联系、可用于降低CV事件风险和预防HF的药物干预和生活方式改变,以及在管理多种合并症时与医疗系统接触的复杂性。讨论强调了患者教育和赋权对于管理T2D心脏相关挑战的重要性,以及多个专科医生之间协作护理在降低T2D患者CV风险方面的核心作用。

相似文献

1
A Podcast on Patient and Physician Perspectives in the Holistic Care of Heart-Related Challenges of Type 2 Diabetes.
Diabetes Ther. 2025 Feb;16(2):137-144. doi: 10.1007/s13300-024-01669-5. Epub 2024 Dec 28.
2
Living with Type 2 Diabetes: Podcast of a Patient-Physician Discussion.
Diabetes Ther. 2023 Apr;14(4):621-627. doi: 10.1007/s13300-023-01378-5. Epub 2023 Mar 2.
3
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Adv Ther. 2019 Oct;36(10):2567-2586. doi: 10.1007/s12325-019-01054-w. Epub 2019 Aug 23.
5
The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.
Prog Cardiovasc Dis. 2019 Jul-Aug;62(4):364-369. doi: 10.1016/j.pcad.2019.08.001. Epub 2019 Aug 10.
6
2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes.
Diabetol Metab Syndr. 2023 Jul 19;15(1):160. doi: 10.1186/s13098-023-01121-x.
8
Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.
Postgrad Med. 2022 May;134(4):376-387. doi: 10.1080/00325481.2021.2009726. Epub 2021 Dec 29.
10
Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?
Diabetes Care. 2020 Jul;43(7):1557-1592. doi: 10.2337/dci20-0017.

本文引用的文献

2
Lifestyle Modification in Heart Failure Management: Are We Using Evidence-Based Recommendations in Real World Practice?
Int J Heart Fail. 2023 Jan 31;5(1):21-33. doi: 10.36628/ijhf.2022.0032. eCollection 2023 Jan.
3
Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.
Circulation. 2023 Feb 21;147(8):e93-e621. doi: 10.1161/CIR.0000000000001123. Epub 2023 Jan 25.
5
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
6
Racial and ethnic disparities in heart failure: current state and future directions.
Curr Opin Cardiol. 2021 May 1;36(3):320-328. doi: 10.1097/HCO.0000000000000855.
8
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
10
Medication Non-Adherence among Patients with Heart Failure.
Cureus. 2019 Aug 8;11(8):e5346. doi: 10.7759/cureus.5346.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验